FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?

BACKGROUND: The aim of the study was to validate the association between the Arg166His polymorphisms of the Fc immunoglobulin receptor 2A (FCGR2A) and the Val212Phe of FCGR3A and pathological clinical response (pCR) to trastuzumab in HER2-positive breast cancer patients. METHODS: Polymorphisms were...

Descripción completa

Detalles Bibliográficos
Autores principales: Botticelli, Andrea, Mazzuca, Federica, Borro, Marina, Mazzotti, Eva, La Torre, Marco, Bonifacino, Adriana, Ciabatta, Francesca Romana, Gentile, Giovanna, Maddalena, Chiara, Simmaco, Maurizio, Marchetti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624668/
https://www.ncbi.nlm.nih.gov/pubmed/28983344
http://dx.doi.org/10.14740/wjon934w
_version_ 1783268277078720512
author Botticelli, Andrea
Mazzuca, Federica
Borro, Marina
Mazzotti, Eva
La Torre, Marco
Bonifacino, Adriana
Ciabatta, Francesca Romana
Gentile, Giovanna
Maddalena, Chiara
Simmaco, Maurizio
Marchetti, Paolo
author_facet Botticelli, Andrea
Mazzuca, Federica
Borro, Marina
Mazzotti, Eva
La Torre, Marco
Bonifacino, Adriana
Ciabatta, Francesca Romana
Gentile, Giovanna
Maddalena, Chiara
Simmaco, Maurizio
Marchetti, Paolo
author_sort Botticelli, Andrea
collection PubMed
description BACKGROUND: The aim of the study was to validate the association between the Arg166His polymorphisms of the Fc immunoglobulin receptor 2A (FCGR2A) and the Val212Phe of FCGR3A and pathological clinical response (pCR) to trastuzumab in HER2-positive breast cancer patients. METHODS: Polymorphisms were characterized by pyrosequencing in 26 patients with ductal histotype breast cancer in a neoadjuvant setting and genotype association with pCR was analyzed. RESULTS: No association was found between the FCGR3A Val212Phe polymorphisms and pCR. In contrast, the FCGR2A GG genotype (Arg allele) was found to be positively associated with pCR (P = 0.012). CONCLUSIONS: Our results do not support previously reported data on the effect of polymorphisms in immunoglobulin Fc receptors upon response to trastuzumab therapy.
format Online
Article
Text
id pubmed-5624668
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elmer Press
record_format MEDLINE/PubMed
spelling pubmed-56246682017-10-05 FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value? Botticelli, Andrea Mazzuca, Federica Borro, Marina Mazzotti, Eva La Torre, Marco Bonifacino, Adriana Ciabatta, Francesca Romana Gentile, Giovanna Maddalena, Chiara Simmaco, Maurizio Marchetti, Paolo World J Oncol Original Article BACKGROUND: The aim of the study was to validate the association between the Arg166His polymorphisms of the Fc immunoglobulin receptor 2A (FCGR2A) and the Val212Phe of FCGR3A and pathological clinical response (pCR) to trastuzumab in HER2-positive breast cancer patients. METHODS: Polymorphisms were characterized by pyrosequencing in 26 patients with ductal histotype breast cancer in a neoadjuvant setting and genotype association with pCR was analyzed. RESULTS: No association was found between the FCGR3A Val212Phe polymorphisms and pCR. In contrast, the FCGR2A GG genotype (Arg allele) was found to be positively associated with pCR (P = 0.012). CONCLUSIONS: Our results do not support previously reported data on the effect of polymorphisms in immunoglobulin Fc receptors upon response to trastuzumab therapy. Elmer Press 2015-10 2015-10-26 /pmc/articles/PMC5624668/ /pubmed/28983344 http://dx.doi.org/10.14740/wjon934w Text en Copyright 2015, Botticelli et al. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Botticelli, Andrea
Mazzuca, Federica
Borro, Marina
Mazzotti, Eva
La Torre, Marco
Bonifacino, Adriana
Ciabatta, Francesca Romana
Gentile, Giovanna
Maddalena, Chiara
Simmaco, Maurizio
Marchetti, Paolo
FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?
title FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?
title_full FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?
title_fullStr FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?
title_full_unstemmed FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?
title_short FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?
title_sort fcgrs polymorphisms and response to trastuzumab in patients with her2-positive breast cancer: far from predictive value?
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624668/
https://www.ncbi.nlm.nih.gov/pubmed/28983344
http://dx.doi.org/10.14740/wjon934w
work_keys_str_mv AT botticelliandrea fcgrspolymorphismsandresponsetotrastuzumabinpatientswithher2positivebreastcancerfarfrompredictivevalue
AT mazzucafederica fcgrspolymorphismsandresponsetotrastuzumabinpatientswithher2positivebreastcancerfarfrompredictivevalue
AT borromarina fcgrspolymorphismsandresponsetotrastuzumabinpatientswithher2positivebreastcancerfarfrompredictivevalue
AT mazzottieva fcgrspolymorphismsandresponsetotrastuzumabinpatientswithher2positivebreastcancerfarfrompredictivevalue
AT latorremarco fcgrspolymorphismsandresponsetotrastuzumabinpatientswithher2positivebreastcancerfarfrompredictivevalue
AT bonifacinoadriana fcgrspolymorphismsandresponsetotrastuzumabinpatientswithher2positivebreastcancerfarfrompredictivevalue
AT ciabattafrancescaromana fcgrspolymorphismsandresponsetotrastuzumabinpatientswithher2positivebreastcancerfarfrompredictivevalue
AT gentilegiovanna fcgrspolymorphismsandresponsetotrastuzumabinpatientswithher2positivebreastcancerfarfrompredictivevalue
AT maddalenachiara fcgrspolymorphismsandresponsetotrastuzumabinpatientswithher2positivebreastcancerfarfrompredictivevalue
AT simmacomaurizio fcgrspolymorphismsandresponsetotrastuzumabinpatientswithher2positivebreastcancerfarfrompredictivevalue
AT marchettipaolo fcgrspolymorphismsandresponsetotrastuzumabinpatientswithher2positivebreastcancerfarfrompredictivevalue

Ejemplares similares